's stock had its "buy" rating restated by stock analysts at D. Boral Capital in a note issued to investors on Wednesday,
Benzinga reports. They currently have a $20.00 target price on the stock.
OS Therapies Stock Performance
Shares of OSTX opened at $2.33 on Wednesday. The stock's 50-day simple moving average is $1.84 and its 200 day simple moving average is $1.73. The stock has a market capitalization of $74.31 million and a price-to-earnings ratio of -2.95. OS Therapies has a 52-week low of $1.12 and a 52-week high of $7.00.
Institutional Trading of OS Therapies
Institutional investors have recently added to or reduced their stakes in the stock. CM Management LLC increased its stake in OS Therapies by 172.6% in the 1st quarter. CM Management LLC now owns 300,000 shares of the company's stock worth $462,000 after acquiring an additional 189,956 shares during the last quarter. XTX Topco Ltd bought a new position in OS Therapies in the 2nd quarter worth about $63,000. Finally, Bridgeway Capital Management LLC bought a new position in OS Therapies in the 2nd quarter worth about $47,000.
About OS Therapies
(
Get Free Report)
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OS Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OS Therapies wasn't on the list.
While OS Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access